Molecular stratification of triple-negative breast cancers.
暂无分享,去创建一个
[1] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] Samuel Leung,et al. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.
[3] Zhiyuan Hu,et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.
[4] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[5] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[6] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[7] Charles M Perou,et al. Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. , 2007, Clinical chemistry.
[8] 黒住 昌史. Breast cancer subtype , 2009 .
[9] Jeffrey M. Rosen,et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.
[10] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[11] R. Tibshirani,et al. Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .
[12] C. Perou,et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Zhiyuan Hu,et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay , 2006, Breast Cancer Research.
[15] Charles M. Perou,et al. Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.
[16] D. Patt,et al. Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC). , 2009 .
[17] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[18] C. Perou,et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. , 2007, Human pathology.
[19] A. Nobel,et al. The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.
[20] C. Perou,et al. Mammary development meets cancer genomics , 2009, Nature Medicine.
[21] C. Perou,et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.
[22] Zhiyuan Hu,et al. A compact VEGF signature associated with distant metastases and poor outcomes , 2009, BMC medicine.
[23] C. Perou,et al. Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy. , 2009 .
[24] C. Perou,et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.